Table 11.
Safety Profiles of DEB-TACE Treatment (333 HCC DEB-TACE Records)
| Parameters | n (%) |
|---|---|
| During DEB-TACE operation | |
| Pain | 183 (55.0) |
| Fever | 123 (36.9) |
| Nausea | 42 (12.6) |
| Vomiting | 35 (10.5) |
| Others | 21 (6.3) |
| 1 month after DEB-TACE operation | |
| Pain | 95 (28.5) |
| Fever | 78 (23.4) |
| Vomiting | 37 (11.1) |
| Nausea | 32 (9.6) |
| Discoloration | 4 (1.2) |
| Bone marrow toxicity | 4 (1.2) |
| Others | 3 (0.9) |
Data are presented as count (%). Description was based on 333 HCC DEB-TACE records. HCC, hepatocellular carcinoma; DEB-TACE, drug-eluting bead transarterial chemoembolization.